NEW YORK – LinusBio said on Wednesday that it is partnering with the nonprofit BRAIN Foundation to advance autism biomarker research and early detection.

纽约——LinusBio公司周三表示，它正在与非营利组织BRAIN基金会合作，推进自闭症生物标志物研究和早期检测。

As part of the collaboration, LinusBio will offer discounts on its ClearStrand-ASD autism test to researchers funded by the nonprofit BRAIN Foundation. The foundation, which funds translational research on treatments to improve the standard of care for comorbidities in individuals with autism, will encourage these researchers to incorporate LinusBio's assay into their research.

作为合作的一部分，LinusBio 将为其ClearStrand-ASD自闭症测试提供折扣，对象是由非营利组织BRAIN基金会资助的研究人员。该基金会资助旨在改善自闭症个体共病治疗标准的转化研究，并将鼓励这些研究人员在其研究中纳入LinusBio的检测方法。

.

。

LinusBio, a spinout of the Mount Sinai School of Medicine, aims to leverage the BRAIN Foundation's network of researchers to further advance autism-related diagnostic tools and therapies.

西奈山医学院分拆出来的LinusBio公司旨在利用BRAIN基金会的研究人员网络，进一步推进与自闭症相关的诊断工具和治疗方法。

ClearStrand-ASD is designed to help physicians rule out autism spectrum disorders (ASD) in children up to 36 months old, where autism is a concern. Using hair samples from infants as young as one month old, the assay scans for biomarkers of how the body responds to certain environmental exposures, such as metal metabolism, which some research has shown to differ between people with and without ASD.

ClearStrand-ASD旨在帮助医生排除36个月以下儿童的自闭症谱系障碍（ASD），特别是当自闭症成为关注点时。该检测使用低至一个月大的婴儿的头发样本，扫描身体对某些环境暴露（如金属代谢）反应的生物标志物，一些研究表明，这些标志物在有和没有ASD的人之间可能存在差异。

.

。

LinusBio calls these exposure-related biomarkers the 'exposome' and hopes that these molecular signatures can provide in-depth molecular insights into ASD pathology needed to help develop objective diagnostic tools for that spectrum of conditions.

LinusBio 将这些与暴露相关的生物标志物称为“暴露组”，并希望这些分子特征能够提供对 ASD（自闭症谱系障碍）病理学的深入分子洞察，以帮助开发针对该系列疾病的客观诊断工具。

The firm, which announced plans to launch its first ASD assay,

该公司宣布计划推出其首个ASD检测方法，

StrandDx-ASD

StrandDx-ASD

, in 2021, is also developing similar tests for other disorders, including schizophrenia, certain gut disorders, and pediatric cancers via its

，2021年，还通过其技术开发针对其他疾病的类似测试，包括精神分裂症、某些肠道疾病和儿科癌症。

StrandDx platform

StrandDx平台

.

。

Financial details of the partnership with the BRAIN Foundation were not disclosed.

与BRAIN基金会合作的财务细节未被披露。

'Objective, biological biomarkers like those developed by LinusBio have the potential to revolutionize early diagnosis, help researchers identify subtypes, predict treatment responses, and track symptom progression over time — advancing both research and care for the autism community,' Sarika Agrawal, cofounder and board member of the BRAIN Foundation, said in a statement.

“像 LinusBio 开发的客观、生物学生物标志物有潜力彻底改变早期诊断，帮助研究人员识别亚型、预测治疗反应，并追踪症状随时间的进展——推动自闭症群体的研究和护理进步，”BRAIN 基金会联合创始人兼董事会成员 Sarika Agrawal 在一份声明中表示。

.

。